Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Therapeutics Acquisition Corp. RACA
$10.27
На 13:47, 16 марта 2023
Ранг: 3
Ключевые показатели
-
Marketcap
1085428424.00000000
-
week52high
18.08
-
week52low
9.81
-
Revenue
-
P/E TTM
0
-
Beta
0.00000000
-
EPS
-
Last Dividend
0.00000000
-
Next Earnings Date
07 мая 2023 г. в 03:50
Описание компании
Therapeutics Acquisition Corp., doing business as Research Alliance Corp. I, intends to effect a merger, capital stock exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the healthcare industry in the United States. The company was founded in 2020 and is based in Boston, Massachusetts.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| HOGUE GERALD L. | A | 25000 | 25000 | 06 июл 2021 г. |
| FLESHNER NEIL E. | A | 25000 | 25000 | 06 июл 2021 г. |
| MARGOLIN YAEL | A | 25000 | 25000 | 06 июл 2021 г. |
| GOODMAN JONATHAN R. | A | 25000 | 25000 | 06 июл 2021 г. |
| DEMERS WILLIAM L. | A | 16767 | 16767 | 06 июл 2021 г. |
| Malik Rajesh | A | 25000 | 25000 | 06 июл 2021 г. |
| GILMOUR MARGARET E. | A | 25000 | 25000 | 06 июл 2021 г. |
| Lubner David Charles | A | 25000 | 25000 | 06 июл 2021 г. |
| JENSEN JESSICA D. | A | 461250 | 461250 | 06 июл 2021 г. |
| GOTTLIEB MICHAEL M. | A | 48000 | 48000 | 06 июл 2021 г. |
Новостная лента
POINT Biopharma Debuts as Publicly Traded Next-Generation Radiotherapeutics Company
GlobeNewsWire
30 июн 2021 г. в 16:05
Common stock to commence trading on the Nasdaq Capital Market on July 1, 2021 under the ticker symbol “PNT”
Research Alliance Corp. I Announces Effectiveness of Registration Statement for Proposed Business Combination with POINT
Business Wire
09 июн 2021 г. в 16:30
BOSTON--(BUSINESS WIRE)--Therapeutics Acquisition Corp, d/b/a Research Alliance Corp. I, a Delaware corporation (“the Company”) (Nasdaq: RACA) announced today that its registration statement on Form S-4 (File Number 333-254600) (as amended, the “Registration Statement”), relating to the previously announced business combination (the “Business Combination”) with POINT Biopharma Inc. (“POINT”), has been declared effective by the U.S. Securities and Exchange Commission (“SEC”) and that it will com
POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC
Business Wire
04 июн 2021 г. в 08:30
INDIANAPOLIS--(BUSINESS WIRE)--POINT Biopharma Inc. (POINT), a global radiopharmaceutical company dedicated to successfully delivering precision radioligand therapy to cancer patients, today announced that it has successfully dosed multiple patients in its Phase 3 SPLASH study evaluating the efficacy of PNT2002, the Company's investigational 177Lu-PSMA targeted radioligand therapy for patients with PSMA expressing metastatic castration resistant prostate cancer (mCRPC) who are not eligible for
POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC
GlobeNewsWire
04 июн 2021 г. в 06:30
INDIANAPOLIS, June 04, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a global radiopharmaceutical company dedicated to successfully delivering precision radioligand therapy to cancer patients, today announced that it has successfully dosed multiple patients in its Phase 3 SPLASH study evaluating the efficacy of PNT2002, the Company's investigational 177Lu-PSMA targeted radioligand therapy for patients with PSMA expressing metastatic castration resistant prostate cancer (mCRPC) who are not eligible for chemotherapy.